Pharma's Almanac: Nice Insight's Content Community

Advanced Therapies

Oct 25, 2024

A New Vision for Progressing Advanced Therapies

In this Q&A, ReciBioPharm’s Nathaniel Youndt discusses the company’s evolving strategy and how it is strategizing to become a leader in nucleic acid manufacturing and drive the future of advanced therapies.

Fast Path to Market: Going from GMP1 to PPQ in Just 12 Months

PPQ

Nov 04, 2024

Fast Path to Market: Going from GMP1 to PPQ in Just 12 Months

This white paper details a landmark project where the company successfully compressed the typical biopharmaceutical development timeline to achieve PPQ from GMP initiation in just 12 months.

Process Development

Sep 24, 2024

Economic Benefits of Digital Process Development

DataHow’s Fabian Feidl, Ph.D., discusses how advanced digital tools and strategies, including quality-by-design, hybrid modeling, transfer learning, and digital twins, not only enhance efficiency in process development but also substantially cut costs in manufacturing.

Transforming xRNA Manufacturing with Digital Technologies and Continuous Processing

Biomanufacturing

Nov 11, 2024

Transforming xRNA Manufacturing with Digital Technologies and Continuous Processing

ReciBioPharm’s flexible, digital xRNA platform revolutionizes RNA biomanufacturing by reducing time and costs, ensuring high-quality production, and enabling global access to advanced therapies.

CDMO

Oct 07, 2024

Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO

NorthX Biologics is a pioneering Swedish contract development and manufacturing organization (CDMO) that combines deep-rooted scientific heritage with cutting-edge biotechnological advancements.

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Biopharma

Sep 27, 2024

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Fab Biopharma’s Reiner Getz, Ph.D., and Gardiner Smith, J.D. discuss how the company aims to revolutionize the treatment of complex and often life-threatening autoimmune diseases like Sjögren’s disease and lupus with its groundbreaking soluble bispecific receptor therapies

Gene Editing

Sep 30, 2024

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Touchlight’s Elena Stoyanova, Ph.D., and Tom Adie, Ph.D., explain how the company’s new nonviral MegaBulb DNA (mbDNA) offers a high-purity, synthetic CRISPR ssDNA template that demonstrates remarkable efficiency and minimal toxicity.

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

Cell Therapy

Sep 30, 2024

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

In this Q&A, OrganaBio’s Chief Executive Officer Justin Irizarry discusses the strategies and operational philosophies driving the company and how it plans to navigate future challenges and opportunities in the rapidly evolving cell therapy landscape.

Building the Future of E. coli Biomanufacturing with Protein Secretion

Technology

Nov 18, 2024

Building the Future of E. coli Biomanufacturing with Protein Secretion

Vectron Biosolutions is advancing E. coli biomanufacturing with its VB Secretion Technology, enabling efficient, large-scale protein production through controlled secretion and continuous platform improvements to support diverse therapeutic and industrial applications.

Clinical Trials

Oct 29, 2024

Passion and Understanding Essential for Rare Disease Clinical Trials

Ergomed’s Juliet Moritz discusses some of the key ongoing challenges sponsors and CROs encounter in implementing effective clinical trials in rare disease and how Ergomed is uniquely positioned to overcome them.

Spotlight

Olon is Ready to Host Productions in the New Facility Dedicated to Ultra-Potent Compounds

Neurocrine Biosciences Presents Breadth of Data Over Time Following Treatment With INGREZZA Capsules

Eisai Completes Submission to US FDA for LEQEMBI Application for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

PCI Pharma Services Wins Supply Chain Excellence Award for Digital Platform to Manage Clinical Trials and Commercial Lifespans

Pharma Tech Industries Names Darrin T. Schellin New CEO

Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets™

Featured Content

Nice Insights

Top 5

Women's Health

Revolutionizing Biologics (and Biology) through a Focus on Women

Top 5

Financing

Oct 15, 2024

Why Life Science Companies Surged amid a Global M&A Downturn

Roundtable

View all roundtable

RoundTable Topics

Outsourcing Dynamics

How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Jeanne Hecht

Ian Scanlon

Ryan Guest, Ph.D.

Jaewon Mun

Sonya Schermann, Ph.D.

Enhanced data analytics, AI, and machine learning are transforming drug discovery and development by enabling more accurate predictions of drug efficacy and safety

View all Answers

Roundtable

View all roundtable

Investment Trends

What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction?

Michael Moussourakis

Tim Tyson

Volker Herrmann

Robert Gustines

Chia Chia Sun

The pharmaceutical and biotech industries are undergoing several new and interesting investment trends. The pandemic activated vast improvements in cleaning/disinfection protocols, communications, vaccine manufacturing, and data management.

View all Answers

RoundTable Topics

Investment Trends

Global Access

Dealing with a Crisis

Digital Connections

INDUSTRIAL INNOVATION

Regulatory

BIOSECURE

Year in Review

Personalized and Precision Medicine

Post-COVID-19 Supply Chain